undamentalytics Newsletter
Sign in

Niagen Bioscience, Inc. (NAGE) stock

Add to watchlist

Add holding +

NASDAQ: NAGE Nasdaq Pharmaceuticals Next results ~November 4, 2026

C+ Fundamentals grade

Niagen Bioscience, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$2.6

Cash-flow model

Base case. Range ~$2.2–$3.2 across our lower- and higher-growth cases (8.9%–18.9% a year).

Price vs value

Modestly undervalued

The price is inside our value range, 10% below our base value.

Price used: $2.35, November 3, 2026

Niagen Bioscience, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling2 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds61 adding, 85 cuttingOf 32 active managers that changed their stake, 16 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Niagen Bioscience files

Where Niagen Bioscience stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $129m, up 11.0% on a year earlier, slower than the 20.8% growth a quarter earlier. Free-cash-flow margin fell to 4.2% from 17.7% a year earlier. Operating margin narrowed to 8.2% from 14.3%. The diluted share count is up 2.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $2.50 a share, against a share price of $2.54.

Source: 10-Q filed August 4, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Niagen Bioscience, Inc.'s trailing-twelve-month revenue grew 11.0% year on year, with a free-cash-flow margin of 4.2%. Where it stands out: days sales outstanding of 24 days ranks 4 of 59 pharmaceuticals companies we cover. Where it lags: change in growth rate of -9.9pp ranks 61 of 74 pharmaceuticals companies we cover.

Our discounted-cash-flow model values the business at ~$2.6 per share in the base case (~$2.2–$3.2 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 73.7% while net income fell 9.8%: a 64pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 9.9 points lower than a quarter earlier.
  • Margins narrowing. Operating margin is down 6.1 points on a year ago.
  • Share dilution. Diluted shares rose 2.5% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 47% and a beta of 1.4 against the S&P 500.
  • Weak cash conversion. Free cash flow was 34% of net income over the last 12 months.

Latest results: FY2026 Q2

Filed August 4, 2026
Earnings per share
$0.01 against an average estimate of -$0.01: beat by 233.0%
Revenue
$30m, down 4.3% on a year earlier
Share reaction
-16.1% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Guidance given
e-commerce business growth growth 10% to 15% (full year 2026)
Next report
November 4, 2026; average EPS estimate -$0.03

Niagen Bioscience's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.3%
  • 1 week-6.2%
  • 1 month-15.9%
  • This year-62.3%
  • 1 year-67.6%
  • 5 years-62.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$129M
Operating margin
8.2%
Net margin
12.4%
EPS (TTM, diluted)
$0.19

Growth

Revenue growth
+11.0%
Change in growth rate
−9.9 pts
Share count change
+2.5%

Cash

Free cash flow (TTM)
$5.4M
FCF margin
4.2%
Stock pay % of revenue
5.4%

Earnings

Last results
August 4, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Niagen Bioscience, Inc. valuation models and calculator

What the price is pricing in

The share price implies about 10.9% a year of cash-flow growth for five years.That is close to the 13.9% a year revenue growth Niagen Bioscience has delivered.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in10.9%
  • Last 12 months11.0%
  • 3 years a year16.8%
  • 5 years a year13.9%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($2.34, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$2.6
Price used
$2.34close November 3, 2026
Implied change
▲ +11%
Uncertainty
Low

How we got here: a discounted-cash-flow model of Niagen Bioscience, Inc.'s free cash flow after stock-based pay with after-tax interest added back ($4.3M, FY2026 Q2 TTM), growing 12.9% and 14.2% in the next two years (forecasts, guidance and its record), then back to 13.9% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$2.2–~$3.2 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Niagen Bioscience, Inc.'s free cash flow after stock-based pay ( $4.3M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Niagen Bioscience, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.85 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$2.6 ~$2.2–$3.2 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$2.7 ~$2.5–$5.5 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$2.6 ~$2.6–$2.7 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Niagen Bioscience, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −17%
  • Revenue growth 5 points higher ▲ +22%
  • Free-cash-flow margin 1 point lower ▼ −16%
  • Last year's free-cash-flow margin change, if it persists ▼ −69%
  • Discount rate 1 point higher ▼ −11%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $2$2$2$3$3$4
8.5% $1$2$2$2$3$3
10% $1$1$2$2$2$3

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$3.66$3.31$5.88$3.43$4.31$4.80$3.74$1.68$1.43$5.31$6.36$2.40
Market value$131m$123m$262m$189m$246m$293m$251m$117m$107m$415m$543m$204m
+ Net debt (− = net cash)$0$0$0−$22m−$9m−$17m−$28m−$20m−$27m−$45m−$65m−$67m
Enterprise value$131m$123m$262m$166m$237m$276m$223m$97m$80m$370m$479m$137m
Multiples
Price / sales 7.3x5.7x12.4x6.0x5.3x4.9x3.7x1.6x1.3x4.2x4.2x1.6x
Price / earnings —————————48.5x31.3x12.7x
Price / free cash flow ————————15.1x34.3x40.2x34.2x
EV / EBITDA —————————44.1x28.3x12.3x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

27 /100

Weak moat

How hard Niagen Bioscience's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -16.2% of total assets over 10 years.

  • Pricing power 18 / 20

    Gross margin has been a median 60.6%, moving by 4.3 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -39.2%; its worst year was -101.1%.

  • Cash conversion 4 / 20

    Free cash flow was positive in 4 of 10 years, at a median -28.8% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 32.7% over five years; stock-based pay has been a median 9.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $34m and EPS of −$0.03 (range −$0.03 to −$0.03) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.00 −100% $133m +3%
Next −$0.06 0% $155m +16%

Next year's EPS estimate has moved −120.7% in 90 days, across 1 analysts.

How the EPS forecast has moved

In the last 30 days, 0 analysts raised Niagen Bioscience, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Niagen Bioscience, Inc., last 90 days
−$0.10 $0.00 $0.10 $0.20 $0.30 90 days ago 60 days ago 30 days ago 7 days ago Now Next fiscal year, 90 days ago: $0.29 Next fiscal year, 60 days ago: $0.10 Next fiscal year, 30 days ago: $0.10 Next fiscal year, 7 days ago: $0.10 Next fiscal year, Now: −$0.06 −$0.06

Average of analysts' published estimates (third-party data).

View chart data
Period Next fiscal year
90 days ago $0.29
60 days ago $0.10
30 days ago $0.10
7 days ago $0.10
Now −$0.06

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.01 $0.01 +233.0%
Mar 2026 $0.06 $0.02 −62.5%
Dec 2025 $0.02 $0.03 +65.6%
Sept 2025 $0.01 $0.05 +233.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026
  • e-commerce business growth full year 2026 10% growth to 15% growth
    “For the full year 2026, the Company expects the e-commerce business to grow 10% to 15% year-over-year.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Niagen Bioscience, Inc.'s revenue by +12.9% next year and +14.2% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+11.6%, weight 45%) and the company's own record (+13.9%, weight 55%) . How the weights are set.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202666
  2. Sep 202666
  3. Aug 202666
  4. Jul 202666

Counts of recommendations published by analysts covering Niagen Bioscience, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.1%
of tradable shares
Days to cover
7.73
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
42%
of shares
Held by insiders
29.5%
of shares
Employees
117
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −68.2%

$7.54 on October 31, 2025 to $2.40

ThenNowEffect
Revenue (last 12 months) $116m $129m +11.0%
Net margin 15.2% 12.4% −18.7%
P/E multiple 35.2x 12.7x −63.8%
Share count 83m 85m −2.4%

Biggest factor: p/e multiple.

Last 3 years +62.2%

$1.48 on November 3, 2023 to $2.40

ThenNowEffect
Revenue (last 12 months) $81m $129m +59.5%
P/S multiple 1.3x 1.6x +18.2%
Share count 73m 85m −13.9%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NAGE−22%−55%−15%+271%+20%−62%
Industry peers (median)−18%−49%−13%−2%+7%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NAGE17%33%50%67%58%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NAGE−80%−70%−42%−44%−56%−66%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 94% from February 25, 2021 to September 26, 2022. Getting back needed a 1475% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.33 – $7.23
From 52-week high
−66.8%
vs 50-day average
−15.6%
vs 200-day average
−38.4%
Volatility (1 year)
47%
Beta vs S&P 500
1.35

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±16.0%
After a week
7 up, 5 down
typical move ±19.1%
After a month
6 up, 6 down
typical move ±35.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 −16.1% +1.6% −12.7% −10.2%
May 6, 2026 −13.1% +1.1% −22.0% −28.4%
March 4, 2026 +4.7% +0.1% +0.4% −10.1%
November 4, 2025 −4.8% −0.8% −1.0% −7.3%
August 6, 2025 +4.9% +0.7% +10.5% +2.7%
May 7, 2025 +5.8% +1.1% +15.7% +48.3%
March 4, 2025 +55.5% −0.1% +43.6% +28.7%
October 31, 2024 +63.7% −1.5% +89.1% +111.2%
August 7, 2024 +2.1% +1.6% +7.1% +18.1%
May 8, 2024 −6.1% +0.6% −3.2% −14.7%
March 6, 2024 −7.5% +1.5% +21.4% +132.4%
November 8, 2023 −7.2% −0.7% −2.0% −12.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Niagen Bioscience, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Niagen Bioscience, Inc.
$80M $100M $120M $140M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $83.4M Revenue (TTM), FY23 Q4: $83.6M Revenue (TTM), FY24 Q1: $83.2M Revenue (TTM), FY24 Q2: $85.6M Revenue (TTM), FY24 Q3: $91.7M Revenue (TTM), FY24 Q4: $99.6M Revenue (TTM), FY25 Q1: $107.9M Revenue (TTM), FY25 Q2: $116.3M Revenue (TTM), FY25 Q3: $124.7M Revenue (TTM), FY25 Q4: $129.4M Revenue (TTM), FY26 Q1: $130.4M Revenue (TTM), FY26 Q2: $129.1M $129.1M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $83.4M
FY23 Q4 $83.6M
FY24 Q1 $83.2M
FY24 Q2 $85.6M
FY24 Q3 $91.7M
FY24 Q4 $99.6M
FY25 Q1 $107.9M
FY25 Q2 $116.3M
FY25 Q3 $124.7M
FY25 Q4 $129.4M
FY26 Q1 $130.4M
FY26 Q2 $129.1M
Revenue growth, TTM YoY Niagen Bioscience, Inc.
0% 10% 20% 30% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 21.2% Revenue growth, TTM YoY, FY23 Q4: 16.0% Revenue growth, TTM YoY, FY24 Q1: 7.5% Revenue growth, TTM YoY, FY24 Q2: 5.7% Revenue growth, TTM YoY, FY24 Q3: 10.0% Revenue growth, TTM YoY, FY24 Q4: 19.2% Revenue growth, TTM YoY, FY25 Q1: 29.8% Revenue growth, TTM YoY, FY25 Q2: 35.9% Revenue growth, TTM YoY, FY25 Q3: 36.0% Revenue growth, TTM YoY, FY25 Q4: 29.9% Revenue growth, TTM YoY, FY26 Q1: 20.8% Revenue growth, TTM YoY, FY26 Q2: 11.0% 11.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 21.2%
FY23 Q4 16.0%
FY24 Q1 7.5%
FY24 Q2 5.7%
FY24 Q3 10.0%
FY24 Q4 19.2%
FY25 Q1 29.8%
FY25 Q2 35.9%
FY25 Q3 36.0%
FY25 Q4 29.9%
FY26 Q1 20.8%
FY26 Q2 11.0%
Operating margin (TTM) Niagen Bioscience, Inc.
-10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -8.2% Operating margin (TTM), FY23 Q4: -6.7% Operating margin (TTM), FY24 Q1: -5.2% Operating margin (TTM), FY24 Q2: -2.7% Operating margin (TTM), FY24 Q3: 0.5% Operating margin (TTM), FY24 Q4: 7.8% Operating margin (TTM), FY25 Q1: 12.3% Operating margin (TTM), FY25 Q2: 14.3% Operating margin (TTM), FY25 Q3: 15.5% Operating margin (TTM), FY25 Q4: 12.6% Operating margin (TTM), FY26 Q1: 10.0% Operating margin (TTM), FY26 Q2: 8.2% 8.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -8.2%
FY23 Q4 -6.7%
FY24 Q1 -5.2%
FY24 Q2 -2.7%
FY24 Q3 0.5%
FY24 Q4 7.8%
FY25 Q1 12.3%
FY25 Q2 14.3%
FY25 Q3 15.5%
FY25 Q4 12.6%
FY26 Q1 10.0%
FY26 Q2 8.2%
FCF margin (TTM) Niagen Bioscience, Inc.
0% 5% 10% 15% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 6.3% FCF margin (TTM), FY23 Q4: 7.5% FCF margin (TTM), FY24 Q1: 4.6% FCF margin (TTM), FY24 Q2: 0.4% FCF margin (TTM), FY24 Q3: 3.8% FCF margin (TTM), FY24 Q4: 11.5% FCF margin (TTM), FY25 Q1: 17.7% FCF margin (TTM), FY25 Q2: 17.7% FCF margin (TTM), FY25 Q3: 16.7% FCF margin (TTM), FY25 Q4: 10.0% FCF margin (TTM), FY26 Q1: 3.0% FCF margin (TTM), FY26 Q2: 4.2% 4.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 6.3%
FY23 Q4 7.5%
FY24 Q1 4.6%
FY24 Q2 0.4%
FY24 Q3 3.8%
FY24 Q4 11.5%
FY25 Q1 17.7%
FY25 Q2 17.7%
FY25 Q3 16.7%
FY25 Q4 10.0%
FY26 Q1 3.0%
FY26 Q2 4.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Jan 2011 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Jan 2015 2015 Jan 2016 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 8 8 12 10 15 18 22 21 32 46 59 67 72 84 100 129 129
Gross profit 3 2 2 3 5 8 10 10 16 26 35 41 43 51 62 83 83
EBITDA −2 −8 −11 −4 −5 −2 −3 −16 −33 −31 −19 −26 −18 −5 8 17 11
Operating income −2 −8 −12 −4 −5 −2 −3 −16 −33 −31 −20 −27 −19 −6 8 16 11
Net income −2 −8 −12 −4 −5 −3 −3 −11 −33 −32 −20 −27 −17 −5 9 17 16
Diluted EPS −$0.12 −$0.12 −$0.13 −$0.04 −$0.15 −$0.08 −$0.08 −$0.26 −$0.61 −$0.56 −$0.33 −$0.40 −$0.24 −$0.07 $0.11 $0.20 $0.19
Growth (year on year)
Revenue — +7.2% +43.1% −12.5% +50.7% +16.8% +21.1% −2.1% +48.8% +46.7% +28.0% +13.8% +6.8% +16.0% +19.2% +29.9% +11.0%
EBITDA — — — — — — — — — — — — — — — +101.3% −35.7%
Operating income — — — — — — — — — — — — — — — +110.7% −36.4%
Net income — — — — — — — — — — — — — — — +103.3% −9.8%
Diluted EPS — — — — — — — — — — — — — — — +81.8% −12.0%
Margins
Gross margin 38.9% 30.5% 19.6% 30.8% 34.8% 42.1% 48.0% 49.4% 50.9% 55.7% 59.5% 61.5% 59.4% 60.8% 61.8% 64.3% 64.2%
EBITDA margin −22.5% −92.9% −97.4% −40.7% −32.7% −10.0% −11.9% −74.8% −103.2% −66.0% −32.0% −38.8% −24.6% −5.7% 8.4% 13.1% 8.6%
Operating margin −26.7% −96.9% −100.2% −43.2% −34.2% −11.6% −13.4% −77.2% −105.1% −67.6% −33.5% −40.1% −25.9% −6.7% 7.8% 12.6% 8.2%
Net margin −27.1% −97.3% −100.4% −43.5% −35.2% −15.5% −13.5% −53.7% −105.6% −69.4% −33.6% −40.2% −23.0% −5.9% 8.6% 13.4% 12.4%
Free-cash-flow margin −37.4% −52.4% −87.4% −39.8% −17.7% −14.7% −20.5% −51.7% −70.4% −45.8% −17.9% −35.8% −21.0% 8.5% 12.2% 10.4% 4.6%
Cash flow
Cash from operations −3 −4 −10 −4 −3 −2 −3 −10 −21 −20 −11 −24 −15 7 12 14 6
Capital spending 0 0 0 0 0 1 2 1 1 1 0 0 0 0 0 0 0
Free cash flow −3 −4 −10 −4 −3 −3 −4 −11 −22 −21 −11 −24 −15 7 12 14 6
Stock-based pay 1 3 3 1 3 2 1 5 6 7 7 6 6 5 4 6 7
Free cash flow after stock pay −4 −7 −13 −5 −6 −5 −6 −16 −29 −28 −18 −30 −21 2 8 7 −1
Balance sheet
Cash 2 — — — — — — — 23 19 17 28 20 27 45 65 67
Total debt — 0 0 0 5 5 0 — 0 10 — 0 0 0 0 0 0
Net debt (negative = net cash) −2 — — — — — — — −22 −9 −17 −28 −20 −27 −45 −65 −67
Diluted shares 16m 25m 32m 34m 35m 36m 37m 45m 55m 57m 61m 67m 70m 75m 78m 85m 85m
Returned to shareholders
Buybacks — — −0 — — — — 0 0 — — — — — 0 0 —
Total returned — — −0 — — — — 0 0 — — — — — 0 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $107m
Short-term assets $98mLonger-term assets $9m
What it owes, and who funded it · $107m
Short-term liabilities $15mLonger-term liabilities $9mShareholders' equity $83m
  • Short-term assets cover short-term liabilities $98m of assets due within a year against $15m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $98m short-term assets against $9m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Niagen Bioscience, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Buybacks, last 3 fiscal years
$655,000
Diluted share count
+2.5%
year over year
R&D spending
5.0%
of revenue
Days sales outstanding
24 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated NAGE ZVRA NAII HRTX ETON AMRN Median
Revenue, last 12 months $129m $136m $143m $151m $106m $176m $276m
Revenue growth, last 12 months 11.0% 119.4% 9.7% 1.0% 81.5% −22.3% 9.9%
Revenue growth, 3-year average 16.8% 101.9% −2.6% 8.6% 53.8% −18.3% 5.5%
Revenue growth, latest quarter −4.3% 53.3% 1.9% 1.3% 98.6% −20.4% 6.5%
Gross margin 64.2% 89.3% 6.3% 70.1% 57.9% 40.9% 62.0%
Operating margin 8.2% 60.5% −13.2% −7.2% 15.4% −18.2% −5.9%
Operating margin, 3-year average 6.6% −149.1% −9.1% −13.5% −2.0% −26.3% −7.4%
Net margin 12.4% 42.8% −14.5% −22.5% 12.0% −10.9% −7.3%
Cash from operations / revenue 4.6% 24.5% −6.3% −7.7% 14.3% 21.3% 10.2%
Free-cash-flow margin 4.2% 24.0% −8.9% −8.0% 14.0% 21.3% 8.6%
Free-cash-flow margin, 3-year average 7.4% −96.2% −3.7% −47.0% 11.7% 1.3% 7.4%
Stock pay / revenue 5.4% 9.6% 0.4% 7.4% 4.9% 4.2% 3.6%
Change in share count 2.5% 13.4% 1.4% 5.9% 29.1% 1.5% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth 11.0% 10.0% 35 of 74
Change in growth rate Growth -9.9pp -0.3pp 61 of 74
Gross margin Profitability 64.2% 59.8% 25 of 59
Operating margin Profitability 8.2% -5.9% 23 of 67
Net margin Profitability 12.4% -7.3% 18 of 75
Free-cash-flow margin Cash generation 4.2% 10.1% 41 of 74
Stock pay as % of revenue Cash generation 5.4% 3.6% 47 of 69
Change in share count Balance sheet 2.5% 1.5% 38 of 62
Days sales outstanding Balance sheet 24 days 72 days 4 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Consumer Products $97.7M 75.5% ▲ 27.2%
Ingredients $28.7M 22.2% ▲ 44.7%
Analytical Reference Standards and Services $3.1M 2.4% ▲ 2.2%
Pharmaceuticals $0 0.0% —

From Niagen Bioscience, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$102M
Institutions reporting
137
Shares held vs prior quarter
▼ 12.8%
Positions opened / closed
22 / 26

Top buyers and sellers, Q2 2026: 61 institutions bought and 85 sold ; the biggest buyer was Jacobs Levy Equity Management, Inc (+325K shares) and the biggest seller Arrowstreet Capital, Limited Partnership (−1.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $13.3M 4.2M 13.1% ▲ 8.1%
Steelpeak Wealth, LLC $11.2M 3.5M 10.9% ▲ 3.8%
Vanguard Capital Management LLC $6.8M 2.1M 6.7% ▼ 0.1%
Tieton Capital Management, LLC $6.4M 2.0M 6.3% ▼ 1.0%
Qube Research & Technologies Ltd $5.2M 1.6M 5.1% ▼ 5.2%
Geode Capital Management, LLC $4.7M 1.5M 4.6% ▲ 9.9%
UBS Group AG $4.1M 1.3M 4.0% ▼ 8.7%
Goldman Sachs Group Inc $4M 1.3M 3.9% ▲ 0.9%
Arrowstreet Capital, Limited Partnership $3.7M 1.2M 3.7% ▼ 50.8%
Vanguard Portfolio Management LLC $3.7M 1.2M 3.6% ▼ 4.5%
State Street Corp $3.5M 1.1M 3.4% ▼ 0.2%
Renaissance Technologies LLC $2.1M 660K 2.1% ▼ 50.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Niagen Bioscience, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $45,616 2 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $45,616 net buying
Insider Date Trade Shares Price Value
Pamir Ozan Chief Financial Officer November 14, 2025 Buy 2,220 $6.85 $15,210
Pamir Ozan Chief Financial Officer November 14, 2025 Buy 4,465 $6.81 $30,406

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 6, 2026
  • March 4, 2026
  • November 4, 2025
  • August 6, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Niagen Bioscience, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Niagen Bioscience, Inc. in brief

What does Niagen Bioscience, Inc. do?
Niagen Bioscience, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Niagen Bioscience, Inc.'s stock ticker?
Niagen Bioscience, Inc. trades under the ticker NAGE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Niagen Bioscience, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Niagen Bioscience, Inc. reported revenue of $129M, 11.0% higher than a year earlier, according to its SEC filings.
What is Niagen Bioscience, Inc.'s free cash flow?
Niagen Bioscience, Inc.'s free-cash-flow margin is 4.2% of revenue over the trailing twelve months, ranking 41 of the 74 pharmaceuticals companies we cover.
What is Niagen Bioscience, Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Niagen Bioscience, Inc.'s free cash flow after stock-based pay gives ~$2.6 per share in the base case, and ~$2.2–$3.2 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Niagen Bioscience, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Steelpeak Wealth, LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Niagen Bioscience, Inc.'s market cap?
On November 2, 2026, Niagen Bioscience, Inc.'s market capitalisation was about $204M, with a price-to-earnings ratio of 12.7 and net debt of -$66.7M. Market figures come from third-party market data and may be delayed.
Who are Niagen Bioscience, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Niagen Bioscience, Inc. are Zevra Therapeutics, Inc., Natural Alternatives International Inc, Heron Therapeutics, Inc., Eton Pharmaceuticals, Inc. and Amarin Corp plc\uk. The side-by-side comparison below sets their revenue, margins and growth against Niagen Bioscience, Inc.'s.
Are insiders buying or selling Niagen Bioscience, Inc. stock?
Over the last 12 months, Niagen Bioscience, Inc.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Niagen Bioscience, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Niagen Bioscience, Inc. announces its own schedule.